An Australian experience with temozolomide for the treatment of recurrent high grade gliomas
- 1 July 2001
- journal article
- research article
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 8 (4) , 325-327
- https://doi.org/10.1054/jocn.2000.0809
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Multicenter Phase II Trial of Temozolomide in Patients With Anaplastic Astrocytoma or Anaplastic Oligoastrocytoma at First RelapseJournal of Clinical Oncology, 1999
- Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical TrialsJournal of Clinical Oncology, 1999
- New chemotherapy options for the treatment of malignant gliomasCurrent Opinion in Oncology, 1999
- Chemotherapy for brain tumors of astrocytic and oligodendroglial lineage: The past decade and where we are headingNeuro-Oncology, 1999
- Patient preferences for oral versus intravenous palliative chemotherapy.Journal of Clinical Oncology, 1997
- Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group.Journal of Clinical Oncology, 1994
- Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumoursEuropean Journal Of Cancer, 1993
- Response criteria for phase II studies of supratentorial malignant glioma.Journal of Clinical Oncology, 1990
- Reporting results of cancer treatmentCancer, 1981